Ontario expands list of vaccinations Canadian pharmacists can administer
TORONTO — Beginning Dec. 15, pharmacists in Ontario will be able to add 13 vaccinations to the list of immunziations they can administer to their patients as part of the province's new strategy, Immunization 2020, which focuses on improving access to immunizations, including leveraging the professional and convenient care that pharmacists offer to help improve vaccination rates.
"We applaud the Ontario government for recognizing the value pharmacists bring by allowing them to administer these vaccinations," stated Jeff Leger, EVP pharmacy and healthcare, Shoppers Drug Mart. "Flu vaccination rates have increased in the province since pharmacists have been able to immunize; allowing them to administer additional vaccines in the future is an important next step in helping to protect Ontarians' health both here and abroad."
The vaccines added to the repertoire include:
- Bacille Calmette-Guérin (BCG);
- Haemophilus Influenzae Type B (Hib);
- Hepatitis A;
- Hepatitis B;
- Herpes Zoster (Shingles);
- Human Papillomavirus (HPV);
- Japanese Encephalitis;
- Meningococcal disease;
- Pneumococcal disease;
- Varicella; and
- Yellow Fever.
These vaccines can be administered in participating pharmacies to anyone five years of age and older.
Not all vaccines require a prescription from a primary care provider, Ontario's Ministry of Health and Long-Term Care announced. In some cases, patients will be able to consult directly with their pharmacist and receive the vaccine at their pharmacy.
However, vaccines that are part of Ontario's publicly funded immunization program are free if administered by a primary care provider. Patients who choose to receive vaccines from a participating pharmacist will have to pay for the vaccine.
The publicly funded flu vaccine will continue to be available at no cost for all Ontarians from their primary care providers and in participating pharmacies.
Ontarians have embraced the opportunity to get their flu vaccination from pharmacists. When that service first became available during the 2012-2013 flu season, more than 250,000 Ontarians were vaccinated by pharmacists. During the most recent flu season, 2014-2015, that number more than tripled to approximately 764,000 Ontarians, Shoppers Drug Mart reported.
McKesson showcases new central fill solution at ASHP Mid-Year Clinical Meeting
LAS VEGAS – McKesson's High Volume Solutions group on Friday announced the launch of Central Fill as a Service (CFaaS), a McKesson-operated, centralized solution that allows pharmacies to use central fill without the investment in equipment, inventory or staffing (other than a pharmacist). Instead of the traditional central fill model that requires significant upfront investment, CFaaS is available to customers through a per-prescription fee that can dramatically reduce the pharmacy’s per-prescription cost to dispense.
“We are excited to offer this new service to our customers who traditionally have not been able to take advantage of our Central Fill solutions,” stated Joe Tammaro, VP Sales, McKesson High Volume Solutions. “Central Fill as a Service allows our customers to benefit from a combination of many assets and tools available from McKesson, including distribution, inventory optimization, industry-leading pharmacy management systems, 340B inventory management and extensive central fill operational expertise.”
CFaaS incorporates McKesson’s industry-leading Central Fill pharmacy automation technology and operational expertise, integrated pharmacy workflow, vast pharmaceutical distribution network and patent-pending streamlined 340B ordering and inventory capabilities to create new revenue and cost savings opportunities for pharmacies that may not have the resources to build their own central fill facility. A team of McKesson High Volume Solutions pharmacy automation experts will work with each CFaaS customer to tailor the service to meet their specific business objectives.
Small chain pharmacies can benefit from CFaaS through increased efficiencies, reduced costs and a greater focus on patient care. This differentiation for small chains can help show value in patient care through a focus on payer performance criteria, including medication adherence.
And pharmacies that already operate a central fill facility in need of an upgrade may benefit from CFaaS as an alternative to investing capital in new or additional equipment. In addition, pharmacies can use the service to increase revenue by pursuing business in new markets such as Employee Fills, Mail Order, Specialty, 340B or Long Term Care.
McKesson is showcasing this new service along with its comprehensive suite of technology solutions and clinical expertise designed to help pharmacy leaders improve financial outcomes, increase supply chain efficiency and leverage actionable insights at the American Society of Health-System Pharmacists Midyear Clinical Meeting 2016, which runs from Dec. 4–8, 2016.
“Pharmacists are increasingly expected to champion initiatives designed to increase revenue and reduce costs while improving efficiency and patient care,” commented Mark Eastham, SVP and general manager, McKessonPharmacy Optimization. “Our pharmacy team, a group of trusted advisors that work with health systems to help elevate the value that pharmacy brings to the health system, can help identify opportunities and work with hospital pharmacies to achieve success in critical areas such as patient safety and quality outcomes: rigorous financial performance, employee collaboration for operational efficiency and integration of critical technology systems.”
Visitors to McKesson's ASHP booth will learn how the power of “&” can work for them by taking advantage of the McKesson's one-on-one consulting. Attendees of ASHP will have the opportunity to engage in one-on-one conversations with McKesson Pharmacy Optimization consultants. During this time, attendees can learn about best practices and solutions to challenges ranging from supply chain efficiency, to specialty and ambulatory pharmacy, to 340B and drug spend analysis. Additionally, McKesson experts will offer 10-minute hands-on training sessions to help customers manage drug shortages, drug spend and drug ordering.
Camber Pharmaceuticals and Hetero Drugs support World AIDS Day
PISCATAWAY, N.J. – As one of the world's largest manufacturers of anti-retroviral drugs for the treatment of HIV/AIDS, Camber Pharmaceuticals and its parent company Hetero Drugs on Thursday expressed its support for World AIDS Day.
"On this day let us come together to express our solidarity for the victims and also to learn about this pandemic," the companies stated.
Hetero is one of India’s leading generic pharmaceutical companies and is the world’s largest global producer of ARVs for the treatment of HIV/AIDS, providing medicines to more than 4.3 million patients globally, or one in every three HIV/AIDS patients.
Hetero’s active pharmaceutical ingredients are supplied to several finished dosage companies, accounting for an additional 7 million patients.